IGC Pharma
26 hedge funds and large institutions have $1.46M invested in IGC Pharma in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 9 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
73% more call options, than puts
Call options by funds: $38K | Put options by funds: $22K
0.08% less ownership
Funds ownership: 3.9% → 3.82% (-0.08%)
16% less funds holding
Funds holding: 31 → 26 (-5)
38% less capital invested
Capital invested by funds: $2.37M → $1.46M (-$906K)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$72.4K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$63K |
| 3 |
Goldman Sachs
New York
|
+$34.8K |
| 4 |
BlackRock
New York
|
+$9K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.91K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$85K |
| 2 |
Jane Street
New York
|
-$73K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$23K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$16K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$11.1K |
IGC Hedge Fund Activity: Q3 2019 in Review
26 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q3 2019, worth a combined $1.46M — down 38% from $2.37M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of IGC and 4 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 7 added.
The largest buyer was Geode Capital Management, adding an estimated $72.4K. The largest seller was Virtu Financial, exiting entirely with an estimated $85K sold.
- 26 institutional investors held IGC Pharma (IGC) as of Q3 2019, down from 31 in Q2 2019.
- Funds reported $1.46M of IGC Pharma stock for Q3 2019, down 38% quarter-over-quarter.
- 4 funds opened new IGC Pharma positions in Q3 2019 and 9 closed out, a net change of -5 holders.
- The largest IGC Pharma buyer in Q3 2019 was Geode Capital Management, an estimated $72.4K added.
- The largest IGC Pharma seller in Q3 2019 was Virtu Financial, an estimated $85K sold.
Based on aggregated 13F filings for Q3 2019.